PIN2 THE NATIONAL HEALTH FOUND BUDGET IMPACT ANALYSIS OF INFLUENZA VACCINATION REIMBURSEMENT IN CHILDREN WITH MALIGNANCIES IN POLAND  by Dardzinski, W et al.
German. Leaving aside the forward translation and back trans-
lation stages, where the whole text is changed, the grid for each
stage was reviewed, and changes counted. The types of changes
were also considered, to evaluate what each step contributes to
the overall translation process. RESULTS: 1) The reconciliation
stage and second forward translation allowed the investigator to
reconsider their own forward translation and make improve-
ments; 2) the back translation review caught some items where
the translation required improvement; 3) only minor changes
were necessary at developer review stage; 4) harmonisation
allowed tweaks to be made so that all language versions were
conveying the same meanings; 5) very few changes were needed
following pilot testing; and 6) proofreading caught grammatical
and formatting errors. CONCLUSION: As the translations went
through the methodology, improvements to the quality and accu-
racy were made. The forward and back translation processes iron
out problematic wordings. Although in terms of numbers of
changes the developer review and pilot testing appear to have
little effect, these stages serve as an important check of the
previous steps. Without harmonisation, the versions may not
have been so close in meaning. Proofreading is an important step
in removing formatting and grammatical errors that may have
crept in when creating the formatted documents from the grids
used for the translation process.
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EFFECTS OF COMORBID CONDITIONS AMONGTHE
OVERWEIGHT/OBESE ON WORK PRODUCTIVITY LOSS
AND ACTIVITY IMPAIRMENT
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OBJECTIVES: To assess the effects of comorbid type 2 diabetes,
high cholesterol or hypertension on work productivity loss
and activity impairment among overweight/obese individuals.
METHODS: The study sample consisted of individuals who
responded to the National Health and Wellness Survey (NHWS)
between March and June of 2006. The NHWS is a nationally
representative, annual, Internet-based survey of non-
institutionalized adults aged 18 and older. It gathers information
regarding respondent demographics, health status, and out-
comes. Overweight/obesity was deﬁned as BMI > 27. Analyses
were conducted on the 19,759 respondents who ﬁt this criterion.
Respondents reported diagnoses of three comorbid conditions:
type 2 diabetes, high cholesterol, hypertension. The Work Pro-
ductivity and Activity Impairment Questionnaire was used to
assess lost productivity and impairment. Linear regression
models were used to determine the independent effects of com-
binations of the three comorbid conditions on productivity loss
and activity impairment. RESULTS: Among obese respondents,
59.35% had at least one of the three speciﬁed comorbid condi-
tions. Individuals with comorbidities were older (diabetes, mean
age 56.9 versus 48.1, p < 0.001) and less likely to be employed
full-time (hypertension 30.9% versus 48.3%, p < 0.001). Signiﬁ-
cant differences were noted between those with and without the
conditions in bivariate analysis. Greater work productivity loss
was observed for those with diabetes (26.0% versus 20.2%,
p < 0.001), high cholesterol (24.1% versus 19.5%, p < 0.001)
or hypertension (24.4% versus 19.2%, p < 0.001). Increased
impairment with daily activities was reported among those with
diabetes (27.1% versus 21.2%, p < 0.001), high cholesterol
(25.7% versus 20.2%, p < 0.001), or hypertension (25.5%
versus 20.2%, p < 0.001). After controlling for confounders, the
presence of all three comorbid conditions was the strongest
correlate of work productivity loss and activity impairment in
multivariate analyses (B = 13.992, p < 0.001 & B = 13.397,
p < 0.001 respectively). CONCLUSION: Overweight\obese indi-
viduals with multiple comorbid conditions reported signiﬁcantly
higher work productivity loss and impairment with daily
activities.
INFECTION—Clinical Outcomes Studies
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OBJECTIVES: To evaluate the safety of antiretroviral therapies
(ART) in decreasing the risk of mother-to-child transmission
(MTCT) of HIV infection. METHODS: Clinical trials of ART
aimed at decreasing the risk of MTCT was systematically iden-
tiﬁed through electronic searches (MEDLINE, EMBASE, BIOSIS,
EBM review, and the Cochrane Library) up until November
2006. Historical search through the reference lists of relevant
articles was also undertaken. For a trial to be included, it had to
be randomized controlled trial of any ART aimed at decreasing
the risk of MTCT and reporting safety data in mothers and/or
infants. The safety was estimated using RR, RD, and NNT
together with 95% conﬁdence intervals. RESULTS: Eleven trials
were included in the meta-analysis. MTCT prophylaxis with
zidovudine monotherapy and the combination with lamivudine
were not associated with congenital abnormality, short-term
hematological, and laboratory toxicities both among pregnant
women and infants. The zidovudine alone or in combination
with lamivudine caused no more adverse events than placebo.
MTCT prophylaxis with nevirapine was not associated with rash
or hepatotoxicity or any serious adverse events among pregnant
women when compared with zidovudine alone or in combination
with lamivudine. CONCLUSION: This systematic review sug-
gests that antiretroviral therapies are safe when used for prevent-
ing MTCT.
INFECTION—Cost Studies
PIN2
THE NATIONAL HEALTH FOUND BUDGET IMPACT ANALYSIS
OF INFLUENZAVACCINATION REIMBURSEMENT IN
CHILDREN WITH MALIGNANCIES IN POLAND
Dardzinski W,Wojcik R,Walczak J, Nogas G
Arcana Institute, Cracow, Poland
OBJECTIVES: To estimate the impact on the National Health
Found budget of infuenza vaccination (Inﬂuvac®) reimburse-
ment in children with malignancies in Poland. METHODS:
Two strategies were compared: inﬂuenza vaccination and
no-vaccination. Population: children with malignancies, <15
years. Proposed vaccination program coverage: 2000 children.
Expected consequences of vaccination on direct medical costs,
related to ﬂu management were assessed and costs of vaccination
in proposed population were calculated. Analysis model was
performed using Polish cost and partly Polish clinical data from
published sources. RESULTS: In proposed population of 2,000
children with malignancies in one year time horizon in Poland
reimbursement costs were 120,000 PLN. Saving due to iﬂuenza
vaccination were 11.75 PLN per oe vaccinated children. Costs
reduction in vaccinated population were mostly dependent on ﬂu
complications incidence and related costs reduction. Expected
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savings for the National Health Found budget in consequence of
inﬂuenza vaccination in proposed population were 23,000 PLN.
CONCLUSION: Reimbursement of inﬂuenza vaccine (Inﬂu-
vac®) in children with malignancies in Poland would be cost
saving for, at least, the National Health Found budget. Further
analysis from social perpactive, including direct non-medical and
indirect costs, should be performed.
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OBJECTIVES: Although most deaths from inﬂuenza occur
among elderly people, all age groups are affected by inﬂuenza
infections. This illness is responsible for signiﬁcant epidemiologi-
cal and economic burden to the working age population. Inﬂu-
enza vaccination has been demonstrated to reduce this impact,
however few information concerns Eastern Europe countries.
This study was designed to determine the effectiveness of inﬂu-
enza vaccination in healthy working adults in Russia and the
economic beneﬁts of such a program from an employer perspec-
tive. METHODS: A prospective, non-randomized, non-placebo
cost-beneﬁt study was conducted involving two groups: vacci-
nated and non-vaccinated. A 9-month follow-up was done
(October 2005–May 2006) using different questionnaires: one at
inclusion to collect general employee information; an other one,
one week after vaccine injection to collect post-vaccination
adverse events; and the last questionnaire was used monthly to
collect Inﬂuenza Like Illness (ILI) events, duration of symptoms
and sick leave associated. Effectiveness calculations and cost-
beneﬁt analyses were performed to evaluate the impact of inﬂu-
enza vaccination program in optimizing the productivity of
employee and the return on investment for the employer.
RESULTS: In all, 1331 volunteers joined the study: 630 in the
vaccinated group and 701 in the non-vaccinated group. The
attack rate of ILI was lower among vaccinated (6.8%) than
non-vaccinated subjects (23.2%). The effectiveness rates of inﬂu-
enza vaccine have reached 70.4% in reducing ILI occurrence and
80.8% in reducing sick leave days. 5.4€ per employee were
invested for the vaccination. Assuming that employees working
while experiencing ILI symptoms have a reduced level of produc-
tivity (30 to 70% of normal), the mean cost of disease avoided
thanks to vaccination was between 7.5 and 10.8€. CONCLU-
SION: This study showed that ILI episodes had signiﬁcant
impact on work productivity. Inﬂuenza vaccination programs
can decrease this impact and leads to cost-saving for the
employer.
PIN4
COST-BENEFIT ANALYSIS OF OSELTAMIVIRVERSUS NO
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OBJECTIVES: To perform a cost-beneﬁt analysis of oseltamivir
versus no antiviral treatment for Roche Brazil employees who
were infected with inﬂuenza during the year of 2006.
METHODS: A cost-beneﬁt model was developed to compare the
costs of two treatment alternatives; Oseltamivir and no antiviral
treatment for inﬂuenza. A decision-tree model based on O’Brian,
B. et al, 2003 was built to simulate the course of the inﬂuenza
infection. The number of workdays lost at Roche Brasil were
derived from a retrospective analysis based on patient records
and then compared with four different studies (Yoichiro et al.
2006, Rothberg, et al. 2005, Akazawa, et al. 2003 e Postma,
et al. 2005). A one-year timeframe was used for the comparison.
A total of 73 inﬂuenza cases were observed during the year of
2006 at Roche Brazil. Direct medical costs were obtained from
the HMO responsible for Roche employees. Indirect costs related
to absenteeism were based on a human capital approach consid-
ering the company expenses with personnel (salary + fringe ben-
eﬁts) as the workday value for each worker. Discounting was not
included due to the short-term perspective of the analysis.
RESULTS: Total costs were R$ 20,198 for oseltamivir treatment
group, and for the no antiviral treatment group total costs ranged
from R$ 41,062 to R$ 55,261 depending on the study utilized.
The cost-savings observed for oseltamivir were due to lower
absenteeism costs (diference between the two groups ranged
from from R$ 26,842 to R$ 41,040) and its less frequent disease
complications. Multi-way Sensitivity analyses conﬁrmed the
robustness of the results obtained. CONCLUSION: The analysis
suggests that providing oseltamivir would incur in a substantial
beneﬁt for the employer. It worth to remind that the size of the
beneﬁt is also related to the company’s health care program (e.g.
vaccination coverage).
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OBJECTIVES: Increasing rates of resistance to antimicrobial
therapy increase the risk of therapeutic failure and impose a
challenge on therapy of infections. Thereby, resistant microor-
ganisms lead to a signiﬁcant increase in patient morbidity, mor-
tality, and health care costs. Tigecycline, a glycylcycline, offers a
broad-spectrum of activity including resistant pathogens such as
methicillin-resistant Staphylococcus aureus (MRSA). In order to
assess the cost-effectiveness of Tigecycline vs. selected standard
antibiotics, we modeled its use in the treatment of complicated
intra-abdominal infections (cIAI). METHODS: A decision-
analytic model was developed and adapted to estimate expected
outcomes and costs of initial antibiotic therapy. Tigecycline
therapy was compared with ceftriaxone/metronidazole, cipro-
ﬂoxacin/metronidazole, imipenem/cilastatin and levoﬂoxacin/
metronidazole. We used published data on pathogen prevalence,
in-vitro eradication rates, length of stay (LOS), failure rates and
mortality in order to populate the model. Information on inpa-
tient costs and drug costs were derived from ofﬁcial databases.
RESULTS: Overall success rate of initial tigecycline therapy
was 89%. Ceftriaxone/metronidazole (71%), ciproﬂoxacin/
metronidazole (70%), imipenem (82%), levoﬂoxacin/
metronidazol (76%) showed lower suc-cess rates. LOS was
shortest with tigecycline therapy (13.8 d vs. 15.1, 15.1, 14.3,
14.7 respectively). Cost-effectiveness of tigecycline was better
than for all comparators (6631.76€ vs. 8542.42€, 9200.67€,
7251.55€ and 7925.48€ per treatment success). Tigecycline
therapy was dominant, e.g. it was more ef-fective than all other
regimens at lower total costs. CONCLUSION: The model indi-
cates that empirical therapy with tigecycline is more cost-effective
than standard antibiotic regimens.
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